About Rahim Kanji
Dr Rahim Kanji is a Consultant Interventional Cardiologist who provides expert care across the full spectrum of cardiovascular disease. He combines clinical excellence, academic expertise and innovative practice to help patients understand their heart health, reduce future cardiovascular risk and access advanced treatment when required.
He sees patients with chest pain, breathlessness, palpitations, dizziness, blackouts, high blood pressure, high cholesterol, coronary artery disease, heart valve disease and heart failure, as well as individuals seeking a detailed assessment of their cardiovascular health and future risk. Whether a patient has symptoms, an established cardiac condition or simply wishes to take a proactive approach to their heart health, Dr Kanji provides personalised, evidence-based care tailored to their individual needs.
Cardiovascular Prevention & Risk Assessment
While Dr Kanji cares for patients across the full spectrum of cardiovascular disease, a major focus of his practice is cardiovascular prevention and risk assessment. Many heart attacks and strokes occur in people who previously felt well, making early identification of risk critically important.
He uses detailed clinical assessment alongside advanced imaging, biomarker testing and validated risk prediction tools to provide a precise understanding of cardiovascular risk. This allows him to develop tailored prevention strategies designed to reduce long-term cardiovascular events and optimise future heart health.
Coronary Intervention & Acute Cardiology
Alongside prevention, Dr Kanji is an experienced interventional cardiologist with particular expertise in coronary artery disease, angina and heart attacks. He performs coronary angiography and coronary angioplasty with stent implantation, using modern intravascular imaging to optimise outcomes, minimise the risk of stent failure and recurrent events, and personalise treatment.
He also provides emergency care for patients presenting with acute heart attacks within his NHS practice.
Academic & Research Background
Dr Kanji graduated with distinction from Imperial College London, where he obtained his medical degree and BSc in Endocrinology. He subsequently completed a PhD at the National Heart and Lung Institute, Imperial College London, focusing on risk stratification in coronary artery disease and aortic stenosis.
His research examined how clinical characteristics, biomarkers and imaging can be used to identify individuals at greatest risk of adverse cardiovascular outcomes. This expertise continues to directly inform his clinical practice, particularly in patients who are at increased cardiovascular risk, but may not yet have symptoms.
NHS, Innovation & Leadership
He holds consultant posts at Chelsea and Westminster Hospital NHS Foundation Trust and Hammersmith Hospital, part of Imperial College Healthcare NHS Trust—both internationally recognised centres for the delivery of high-quality cardiovascular care and clinical excellence.
Dr Kanji is Clinical Lead for the Virtual Chest Pain Ward at Chelsea and Westminster Hospital, where he has helped develop one of the UK's leading virtual cardiology services. Through this innovative model of care, patients can receive specialist cardiovascular assessment and treatment safely and effectively from their own homes.
The team’s work in this field has received national attention, including a live Sky News interview in which Dr Kanji discussed the evolution of virtual wards and their role in improving patient care and efficiency across the NHS. (Live SKY news interview)
This commitment to innovation and patient-centred care has also been recognised by the Royal College of Physicians. In 2025, Dr Kanji and his colleagues were awarded the Royal College of Physicians Excellence in Patient Care Award in recognition of their work to improve patient outcomes and develop innovative models of cardiovascular care.
Education & Academic Role
Alongside his clinical practice, Dr Kanji remains actively involved in research, education and innovation. He is an Honorary Senior Clinical Lecturer at the National Heart and Lung Institute, Imperial College London, where he lectures and examines on the BSc, MSc and undergraduate medical programmes.
He is actively involved in teaching and training future doctors and cardiologists and regularly teaches GPs, specialist trainees and healthcare professionals at both national and international level.
Dr Kanji is widely published in cardiovascular medicine, with particular expertise in thrombosis, heart attacks and antiplatelet therapy.
Patient-Focused Care
Above all, Dr Kanji is committed to helping patients achieve the best possible cardiovascular health at every stage of life. Whether assessing future risk, investigating symptoms, managing complex disease or performing coronary intervention, he combines the latest evidence with a highly personalised approach to care.
His goal is not only to treat cardiovascular disease, but to prevent it wherever possible and help patients live longer, healthier and more confident lives.
Patient Reviews
Patients frequently comment on Dr Kanji’s compassionate approach, clear explanations and commitment to delivering personalised, high-quality care. Many describe feeling listened to, reassured and fully informed throughout their treatment journey.
To read patient testimonials and verified Google Reviews, please visit: https://heartcarebyrk.com/
Expertise
- Chest Pain
- Breathlessness
- Palpitations
- Heart Failure
- Valvular and Structural Abnormalities
- Arrhythmias
- Hypertension
- Hypercholesterolaemia
- Heart Attacks
- Angina
- Invasive Angiography
- Angioplasty
Overview
- Age of patients seen
- 18+
- Qualifications
BSc (Hons), MBBS, PhD, MRCP
- Languages spoken
- English
- Research highlights
Dr Kanji has several publications in peer-reviewed journals, and actively speaks at national and international conferences, including Diabetes Professional Care, Cardio Renal Metabolic UK Summit, EuroThrombosis EuroVessels and British Society for Haemostasis and Thrombosis.
Publications include:
Kanji R, Gue YX, Memtsas V, Spencer NH, Gorog DA. Biomarkers of Thrombotic Status Predict Spontaneous Reperfusion in Patients With ST-Segment Elevation Myocardial Infarction. J Am Coll Cardiol. 2023 May 16;81(19):1918-1932. doi: 10.1016/j.jacc.2023.03.388. PMID: 37164525.
https://pubmed.ncbi.nlm.nih.gov/37164525/Kanji R, Gue YX, Farag MF, Spencer NH, Mutch NJ, Gorog DA. Determinants of Endogenous Fibrinolysis in Whole Blood Under High Shear in Patients With Myocardial Infarction. JACC Basic Transl Sci. 2022 Aug 24;7(11):1069-1082. doi: 10.1016/j.jacbts.2022.05.007. PMID: 36687271; PMCID: PMC9849272.
https://pubmed.ncbi.nlm.nih.gov/36687271/Kanji R, Leader J, Memtsas V, Gorog DA. Measuring Thrombus Stability at High Shear, Together With Thrombus Formation and Endogenous Fibrinolysis: First Experience Using the Global Thrombosis Test 3 (GTT-3). Clin Appl Thromb Hemost. 2023 Jan-Dec;29:10760296231181917. doi: 10.1177/10760296231181917. PMID: 37551011; PMCID: PMC10411283.
https://pubmed.ncbi.nlm.nih.gov/37551011/Kanji R, Vandenbriele C, Arachchillage DRJ, Price S, Gorog DA. Optimal Tests to Minimise Bleeding and Ischaemic Complications in Patients on Extracorporeal Membrane Oxygenation. Thromb Haemost. 2022 Apr;122(4):480-491. doi: 10.1055/a-1508-8230. Epub 2021 Jun 21. PMID: 33984868.
https://pubmed.ncbi.nlm.nih.gov/33984868/Kanji R, Gue YX, Memtsas V, Gorog DA. Fibrinolysis in Platelet Thrombi. Int J Mol Sci. 2021 May 12;22(10):5135. doi: 10.3390/ijms22105135. PMID: 34066261; PMCID: PMC8152010.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8152010/Kanji R, Jenner WJ, Mirsadraee S, Gue YX, Price S, Prasad S, Gorog DA. Thrombotic complications in 2928 patients with COVID-19 treated in intensive care: a systematic review. J Thromb Thrombolysis. 2021 Apr;51(3):595-607. doi: 10.1007/s11239-021-02394-7. Epub 2021 Feb 14. PMID: 33586113; PMCID: PMC7882250.
https://pubmed.ncbi.nlm.nih.gov/33586113/Kanji, R., Mirsadraee, S., Prasad, S., Gue, Y. X., Panoulas, V., & Gorog, D. A. Thrombosis Risk with Transcatheter Aortic Valve Replacement. Structural Heart. 2020 4(5), 349–359.
https://doi.org/10.1080/24748706.2020.1797256Kanji R, Kubica J, Navarese EP, Gorog DA. Endogenous fibrinolysis-Relevance to clinical thrombosis risk assessment. Eur J Clin Invest. 2021 Apr;51(4):e13471. doi: 10.1111/eci.13471. Epub 2020 Dec 16. PMID: 33296082.
https://pubmed.ncbi.nlm.nih.gov/33296082/Gue YX, Memtsas V, Kanji R, Wellsted DM, Busby A, Smith M, Vilar E, Ryding A, Arachchillage DJ, Gorog DA. Impact of very low dose rivaroxaban in addition to dual antiplatelet therapy on endogenous fibrinolysis in acute coronary syndrome: The VaLiDate-R study. Thromb Res. 2024 Apr;236:144-154. doi: 10.1016/j.thromres.2024.02.030. Epub 2024 Mar 3. PMID: 38447421.
https://pubmed.ncbi.nlm.nih.gov/38447421/Leader JH, Kanji R, Gorog DA. Spontaneous reperfusion in STEMI: Its mechanisms and possible modulation. Kardiol Pol. 2024;82(4):363-374. doi: 10.33963/v.phj.99737. Epub 2024 Mar 17. PMID: 38493469.
https://pubmed.ncbi.nlm.nih.gov/38493469/Gue YX, Kanji R, Wellsted DM, Srinivasan M, Wyatt S, Gorog DA. Rationale and design of "Can Very Low Dose Rivaroxaban (VLDR) in addition to dual antiplatelet therapy improve thrombotic status in acute coronary syndrome (VaLiDate-R)" study : A randomised trial modulating endogenous fibrinolysis in patients with acute coronary syndrome. J Thromb Thrombolysis. 2020 Feb;49(2):192-198. doi: 10.1007/s11239-019-02014-5. PMID: 31872349; PMCID: PMC6969858.
https://pubmed.ncbi.nlm.nih.gov/31872349/Gue YX, Kanji R, Gati S, Gorog DA. MI with Non-obstructive Coronary Artery Presenting with STEMI: A Review of Incidence, Aetiology, Assessment and Treatment. Eur Cardiol. 2020 Apr 30;15:e20. doi: 10.15420/ecr.2019.13. PMID: 32419851; PMCID: PMC7215489.
https://pubmed.ncbi.nlm.nih.gov/32419851/Kanji R, Dinarvand D, GueYX, Gorog DA, Myocardial infarction with non-obstructive coronary arteries in young women presenting with ST-segment elevation myocardial infarction: a case series. Medical Research Journal 2020;5(1):55-60. doi: 10.5603/MRJ.a2020.0006
https://journals.viamedica.pl/medical_research_journal/article/view/67839Gue YX, Sayers M, Whitby BT, Kanji R, Adatia K, Smith R, Davies WR, Perperoglou A, Potpara TS, Lip GYH, Gorog DA. Usefulness of the NULL-PLEASE Score to Predict Survival in Out-of-Hospital Cardiac Arrest. Am J Med. 2020 Nov;133(11):1328-1335. doi: 10.1016/j.amjmed.2020.03.046. Epub 2020 May 7. PMID: 32387318.
https://pubmed.ncbi.nlm.nih.gov/32387318/Gue YX, Adatia K, Kanji R, Potpara T, Lip GYH, Gorog DA. Out-of-hospital cardiac arrest: A systematic review of current risk scores to predict survival. Am Heart J. 2021 Apr;234:31-41. doi: 10.1016/j.ahj.2020.12.011. Epub 2020 Dec 31. PMID: 33387469.
https://pubmed.ncbi.nlm.nih.gov/33387469/Gue YX, Kanji R, Markides V, Gorog DA. Angiotensin Converting Enzyme 2 May Mediate Disease Severity In COVID-19. Am J Cardiol. 2020 Sep 1;130:161-162. doi: 10.1016/j.amjcard.2020.06.002. Epub 2020 Jun 9. PMID: 32636018; PMCID: PMC7282749.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7282749/Gue YX, Tennyson M, Gao J, Ren S, Kanji R, Gorog DA. Development of a novel risk score to predict mortality in patients admitted to hospital with COVID-19. Sci Rep. 2020 Dec 7;10(1):21379. doi: 10.1038/s41598-020-78505-w. Erratum in: Sci Rep. 2021 Apr 7;11(1):8011. doi: 10.1038/s41598-021-87439-w. PMID: 33288840; PMCID: PMC7721695.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7721695/Barbero U, Kanji R, Cerrato E, Di Summa R, Conrotto F, Kawamoto H, Biondi-Zoccai G, Gili S, Ugo F, Iannaccone M, Gagliardi M, De Benedictis M, Doronzo B, Varbella F, D'Amico M, Moretti C, Colombo A, Escaned J, D'Ascenzo F. Unprotected Left Main Coronary Artery Disease: Outcomes of Treatment With Second-Generation Drug-Eluting Stents - Insight From the FAILS-2 Study. J Invasive Cardiol. 2018 Aug;30(8):283-288. Epub 2018 May 15. PMID: 29760284.
https://pubmed.ncbi.nlm.nih.gov/29760284/Barbero U, D'Ascenzo F, Campo G, Kleczyński P, Dziewierz A, Menozzi M, Jiménez Díaz VA, Cerrato E, Raposeiras-Roubín S, Ielasi A, Rognoni A, Fineschi M, Kanji R, Jaguszewski MJ, Picchi A, Andò G, Soraci E, Mancone M, Sardella G, Calcagno S, Gallo F, Huczek Z, Krakowian M, Verardi R, Montefusco A, Omedè P, Lococo M, Moretti C, D'Amico M, Rigattieri S, Gaita F, Rinaldi M, Escaned J. Safety of FFR-guided revascularisation deferral in Anatomically prognostiC diseasE (FACE: CARDIOGROUP V STUDY): A prospective multicentre study. Int J Cardiol. 2018 Nov 1;270:107-112. doi: 10.1016/j.ijcard.2018.06.013. Epub 2018 Jun 8. PMID: 29937300.
https://pubmed.ncbi.nlm.nih.gov/29937300/Kanji R, Gue YX, Dinarvand D, Farag MQ, Gorog DA, Assessment of endogenous fibrinolysis using a point-of-care assay to identify increased cardiovascular risk in patients with diabetes and ACS. European Heart Journal. Volume 41, Issue Supplement_2, November 2020, ehaa946.1540
https://doi.org/10.1093/ehjci/ehaa946.1540R Kanji, Y.X Gue, D Dinarvand, D.A Gorog, No difference in thrombotic profile of patients with ACS with obstructive CAD and MINOCA. European Heart Journal. Volume 41, Issue Supplement_2, November 2020, ehaa946.1541
https://doi.org/10.1093/ehjci/ehaa946.1541
Consultations and services
- Self-pay available from £300
- Health insurance
- 30 mins consultation
- Self-pay available from £225
- Health insurance
- 30 mins consultation
Insurers covered
Tests & treatments
Locations
Loading
Frequently asked questions
Yes, but only for certain services. Some consultations, assessments, and treatments can be booked directly, while others require a GP or specialist referral. Please check the relevant service page for guidance, and contact the centre if you’re unsure.
We aim to offer appointments as quickly as possible, and many services have same-day or next-day availability. Waiting times vary depending on the appointment type, specialty, and consultant availability, but our team will always offer the earliest suitable appointment.
Yes. You can arrange an appointment for a family member, or someone you care for, just let us know when you get in touch. We’ll need their details and consent to complete the booking, unless you're their legal guardian or have power of attorney.
Your first consultation includes a detailed discussion of your symptoms, medical history, and lifestyle factors, followed by a thorough examination. It’s helpful if you can bring the results of any previous investigations with you, as well as a list of your current medications. Come with a comfortably full bladder so you can provide a urine sample if requested.